264 related articles for article (PubMed ID: 19574174)
1. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
2. Hormonal therapy before surgical treatment for uterine leiomyomas.
Moghissi KS
Surg Gynecol Obstet; 1991 Jun; 172(6):497-502. PubMed ID: 1827931
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
4. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
5. Treatment of perimenopausal women with uterine myoma: successful use of a depot GnRH agonist leading to a natural menopause.
Imai A; Sugiyama M; Furui T; Tamaya T
J Obstet Gynaecol; 2003 Sep; 23(5):518-20. PubMed ID: 12963511
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist use before hysterectomy.
Stovall TG; Summit RL; Washburn SA; Ling FW
Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial.
Coddington CC; Grow DR; Ahmed MS; Toner JP; Cook E; Diamond MP
Fertil Steril; 2009 May; 91(5):1909-13. PubMed ID: 18439584
[TBL] [Abstract][Full Text] [Related]
8. GnRH agonist therapy before myomectomy or hysterectomy.
Gutmann JN; Corson SL
J Minim Invasive Gynecol; 2005; 12(6):529-37; quiz 528, 538-9. PubMed ID: 16337584
[No Abstract] [Full Text] [Related]
9. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist.
Wen L; Tseng JY; Wang PH
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):173-5. PubMed ID: 17197363
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
11. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
12. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
13. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
Saltiel E
Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
[TBL] [Abstract][Full Text] [Related]
14. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy.
Cohen D; Mazur MT; Jozefczyk MA; Badawy SZ
J Reprod Med; 1994 May; 39(5):377-80. PubMed ID: 7520497
[TBL] [Abstract][Full Text] [Related]
15. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
16. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
17. Uterine artery embolization as a treatment option for uterine myomas.
Marshburn PB; Matthews ML; Hurst BS
Obstet Gynecol Clin North Am; 2006 Mar; 33(1):125-44. PubMed ID: 16504811
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic uterine vessel occlusion in the treatment of women with symptomatic uterine myomas with and without adding laparoscopic myomectomy: 4-year results.
Wang PH; Liu WM; Fuh JL; Chao HT; Chao KC; Yuan CC
J Minim Invasive Gynecol; 2008; 15(6):712-8. PubMed ID: 18971134
[TBL] [Abstract][Full Text] [Related]
19. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
[TBL] [Abstract][Full Text] [Related]
20. Rationale of myomectomy for perimenopausal women.
Wang PH; Chao HT; Lee WL
Maturitas; 2007 Dec; 58(4):406-7. PubMed ID: 18022333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
